SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-132687
Filing Date
2021-04-27
Accepted
2021-04-27 07:32:00
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A d24332ddefa14a.htm DEFA14A 28746
2 GRAPHIC g243321a.jpg GRAPHIC 4376
3 GRAPHIC g243321b.jpg GRAPHIC 1440
4 GRAPHIC g243321c.jpg GRAPHIC 1446
5 GRAPHIC g243321d.jpg GRAPHIC 1057
6 GRAPHIC g243321e.jpg GRAPHIC 946
7 GRAPHIC g243321f.jpg GRAPHIC 1354
  Complete submission text file 0001193125-21-132687.txt   45262
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39397 | Film No.: 21855881
SIC: 2834 Pharmaceutical Preparations